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To inform mathematical modelling of the impact 
of chlamydia screening in England since 2000, a 
complete picture of chlamydia testing is needed. 
Monitoring and surveillance systems evolved between 
2000 and 2012. Since 2012, data on publicly funded 
chlamydia tests and diagnoses have been collected 
nationally. However, gaps exist for earlier years. We 
collated available data on chlamydia testing and 
diagnosis rates among 15–44-year-olds by sex and 
age group for 2000–2012. Where data were unavail-
able, we applied data- and evidence-based assump-
tions to construct plausible minimum and maximum 
estimates and set bounds on uncertainty. There was 
a large range between estimates in years when data-
sets were less comprehensive (2000–2008); smaller 
ranges were seen hereafter. In 15–19-year-old women 
in 2000, the estimated diagnosis rate ranged between 
891 and 2,489 diagnoses per 100,000 persons. Testing 
and diagnosis rates increased between 2000 and 2012 
in women and men across all age groups using mini-
mum or maximum estimates, with greatest increases 
seen among 15–24-year-olds. Our dataset can be used 
to parameterise and validate mathematical models 
and serve as a reference dataset to which trends in 
chlamydia-related complications can be compared. 
Our analysis highlights the complexities of combining 
monitoring and surveillance datasets.
Introduction
Genital infection with Chlamydia trachomatis (‘chla-
mydia’) is the most commonly diagnosed sexually 
transmitted infection (STI) in Europe [1,2]. If left 
untreated, genital chlamydia infection can cause seri-
ous complications in both women and men, including 
pelvic inflammatory disease (PID), ectopic pregnancy, 
tubal factor infertility and epididymitis [3]. Prevalence 
is generally highest in young adults [4-6]. A recent 
systematic review found estimates of prevalence 
in Europe and other high-income countries among 
sexually-experienced ≤ 26-year-olds ranged from 3.0% 
to 5.3% in women and 2.4% to 7.3% in men [7].
Chlamydia control activities vary across Europe, rang-
ing from case management for diagnosed cases to 
opportunistic testing among asymptomatic individu-
als [8]. In England, in recognition of the public health 
importance of genital chlamydia infection, the National 
Chlamydia Screening Programme (NCSP) was intro-
duced in 2003 and was active nationwide by 2008. The 
programme aims to reduce chlamydial infections and 
associated complications by detecting and treating 
asymptomatic infections through opportunistic screen-
ing. The NCSP recommends all sexually active under-
25-year-olds be tested for genital chlamydia infection 
annually or on change of sexual partner (whichever is 
the most frequent) and those who test positive should 
be offered a re-test around 3 months after treatment 
[3]. Screening is accessible through a range of provid-
ers, which include general practitioners (GPs), phar-
macies, contraception services, sexual health and 
reproductive services and pregnancy termination ser-
vices [9]. In 2013, over 1.7 million chlamydia tests were 
carried out among 15–24-year-olds in both specialist 
sexual health services (genitourinary medicine clinics 
(GUM)) and non-specialist services with over 139,000 
positive chlamydia results reported (hereafter ‘diagno-
ses’ refers to ‘positive chlamydia results’) [10].
Understanding changes in chlamydia tests and diag-
nosis will better inform us of the NCSP’s effects on 
chlamydia infections and can facilitate programme 
evaluation in regards to both genital chlamydia prev-
alence and understanding related complications. 
Gaining an understanding of the NCSP’s impact is also 
useful for other European countries considering the 
optimal approach to chlamydia control [11]. Annual 
data on testing and diagnoses are required for param-
eterisation of mathematical models which explore the 
effect of chlamydia screening on chlamydia prevalence. 
2 www.eurosurveillance.org
As acknowledged by authors of previous mathemati-
cal modelling studies of chlamydia screening, one of 
the limitations of current models is the availability of 
robust data on chlamydia tests and diagnoses in this 
context. A comprehensive overview of testing practices 
before and during NCSP implementation can also facili-
tate interpretation of trends in chlamydia-related com-
plications. However, since 2000, national monitoring 
and surveillance systems that include reported chla-
mydia tests and diagnoses in England have evolved 
considerably [10,12,13] resulting in reporting gaps in 
the data. These gaps include non-reported data from 
specific years, settings or age groups; missing age and 
sex data; and referrals between settings. In this paper, 
we estimate chlamydia testing and diagnosis rates by 
age group among men and women aged 15 to 44 years 
between 2000 and 2012 using data from several data-
sets and a sample of GP records, combined with data-
driven and evidence-based assumptions, to fill the 
gaps in these data. Our estimates of chlamydia testing 
and diagnosis rates are needed to provide robust data 
for mathematical models that can be used to evaluate 
chlamydia control activities.
Methods
Data sources
Data on chlamydia tests and diagnoses were compiled 
from several data sources. The data available varied 
according to the years and test settings covered and 
the extent to which data were provided by age group 
(Figure 1).
Specialist sexual health services
Numbers of chlamydia tests and diagnoses carried out 
in specialist sexual health services were derived from 
the KC60 statistical return (2000–2008) and geni-
tourinary medicine clinic activity dataset (GUMCAD, 
2009–2012). Details of these datasets are reported 
elsewhere [12]. Briefly, the KC60 was a mandatory sta-
tistical return which provided an aggregated dataset of 
diagnoses and services delivered in specialist sexual 
health services in England up to 2008. Between 2000 
and 2002 the number of tests were not recorded; diag-
noses were broken down by sex but not age. Tests 
were included from 2003 and broken down by sex but 
not age; diagnoses were available by sex and age for 
Year 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 2012
Data captured 
in specialist 
sexual health 
services 
Data 
source KC60 statistical return GUMCAD
Data 
available
Number of diagnoses by 
sex a
Number of diagnoses in 
MSM 
Number of tests not 
available a
Number of diagnoses by sex and age group b
Number of tests and diagnoses in MSM 
Number of tests by sex a
Number of tests and diagnoses 
by sex, age group and sexual 
orientation 
Data captured 
in non-
specialist 
services
Data 
source CPRD NCSP statistical return & CPRD
Aggregated laboratory 
returns, NCSP & CPRD CTAD
Data 
available 
CPRD: Number of tests & diagnoses in general practice, by age and sex (15–44 year-olds)
Number 
of tests & 
diagnoses 
by sex and 
age (all 
ages)
NCSP statistical returns: Number of tests & diagnoses through the 
NCSP by age and sex, 15–24 year-olds
Aggregated laboratory 
returns: Number of tests 
and diagnoses outside 
NCSP by sex and age 
group, 15–24 year-olds
Figure 1
Schematic of available chlamydia activity data from national monitoring and surveillance systems in specialist sexual health 
services and non-specialist services, England, 2000–2012
CPRD:  Clinical Practice Research Datalink; CTAD:  Chlamydia Testing Activity Dataset; GUMCAD: genitourinary medicine clinic activity dataset; 
MSM: men who have sex with men; NCSP: National Chlamydia Screening Programme.
GUMCAD is a collection of electronic patient-level data that captures tests and diagnoses provided in commissioned sexual health services. 
CTAD is a collection of electronic patient-level data that captures all publicly funded chlamydia testing activity and diagnoses in England.
a Includes uncomplicated and complicated chlamydia captured separately from each other in the KC60 statistical return.
b Includes uncomplicated and complicated chlamydia captured separately from each other in the KC60 statistical return but complicated 
chlamydia is not broken down by age group.
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Data from specialist services 
Raw data from English surveillance 
systems for specialist services
1 1
2
2 2
4
3
Raw data from English surveillance 
systems for non-specialist services
Tests and diagnoses of unknown 
age group/sex reallocated
Tests in specialist services 
imputed for 2000 to 2002
Referrals from non-specialist 
to specialist services removed 
(using maximum estimate 
of non-specialist services)
Referrals from non-specialist 
to specialist services removed 
(using minimum estimate 
of non-specialist services)
Estimated tests 
and diagnoses in 
specialist services 
among MSM removed
MAXIMUM 
specialist 
services 
activity
MAXIMUM 
non-specialist 
services 
activity
MINIMUM 
non-specialist 
services 
activity
MINIMUM 
specialist 
services 
activity
Data from non-specialist services
Tests and diagnoses of unknown 
age group/sex reallocated
GP tests 
in NCSP 
statistical 
returns 
dataset 
removeda
Non-specialist 
services 
activity imputed for 
2000 to 2007 
(15–24 year-olds) 
and 2000 to 2011 
(>24 year-olds) 
Figure 2
Flowchart summarising combinations and adjustments to the data from specialist sexual health services and non-specialist 
sexual health services to construct plausible minimum and maximum estimates of chlamydia tests and diagnosis rates by 
sex and age group, England, 2000–2012
GP: general practice; MSM: men who have sex with men; NCSP: National Chlamydia Screening Programme.
Adjustment number 1:  dealing with data of unknown age group or sex; Adjustment number 2: imputing non-reported data from a specific 
year, setting or age group; Adjustment number 3: allowing for referrals from non-specialist to specialist settings; Adjustment number 
4: removal of MSM from the minimum-activity estimate for specialist settings.
a It is unknown whether chlamydia tests carried out in GP settings, but as part of the NCSP, would also be captured within GP records. 
Therefore, where there was potential duplication (2003–2007), GP tests were removed from the NCSP statistical returns dataset.
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uncomplicated chlamydial infections but not available 
by age for complicated chlamydial infections. GUMCAD, 
which was introduced in 2009, is a mandatory disag-
gregated data return of STI diagnoses and services 
provided submitted by all specialist services across 
England [12]. The number of tests and diagnoses are 
available by sex, age and sexual orientation.
Non-specialist sexual health services
Chlamydia tests and diagnoses made outside spe-
cialist sexual health services were derived from three 
nationally collated datasets:
• NCSP statistical returns (2003–2011): a disaggre-
gated return from testing venues of all chlamydia 
tests and diagnoses among 15–24-year-olds tested 
as part of the NCSP between 2003 and September 
2012.
• Aggregated laboratory return (2008–2011): this 
return captured data from all laboratories that col-
lected tests and diagnoses among 15–24-year-olds 
reported from outside of specialist sexual health 
services and not as part of the NCSP between April 
2008 and September 2012 (e.g. in hospitals or in GP 
settings not carried out as part of the NCSP).
• Chlamydia Testing Activity Dataset (CTAD, 2012): 
CTAD is a disaggregated data return from labora-
tories that replaced the NCSP statistical return and 
aggregated laboratory return in 2012. CTAD captures 
all publicly funded chlamydia tests and diagnoses in 
England for all ages [10,13].
Before the introduction of CTAD in 2012, national 
monitoring and surveillance systems in England did 
not cover chlamydia testing carried out among those 
aged 25 years and over attending non-specialist clin-
ics [12,13]. We therefore supplemented the datasets 
described above using data from the clinical practice 
research datalink (CPRD). CPRD comprises anonymised 
patient-level medical records of registered patients in 
a sample (ca 10%) of GPs across the United Kingdom 
(UK) [14-16]. Attendances for chlamydia tests and 
diagnoses among men and women aged 15–44 years 
between 2000 and 2011 were identified using a pre-
defined selection of ‘Read Codes’ (diagnostic codes 
used in primary care, data not shown). Duplicate codes 
within a 42-day period were considered part of the 
same episode and subsequently excluded.
With the exception of data from CPRD, estimates of 
testing coverage (number of tests as a percentage of 
the population) and diagnosis rates (number of diag-
noses per 100,000 population) were calculated using 
population denominators provided from the Office of 
National Statistics [17]. Testing and diagnosis rates 
reported in CPRD were calculated by dividing the num-
ber of tests and diagnoses by the person-years contrib-
uted by the registered practice population in each year 
by sex and age group [14].
Data and evidence base to address the known 
limitations of national monitoring and 
surveillance systems
After combining the datasets, we made a series of 
adjustments to resolve gaps in the data and calculate 
minimum and maximum plausible estimates of chla-
mydia testing coverage and diagnosis rates for each 
age group by sex and year in both specialist and non-
specialist services (Figure 2). We define adjustments 
to the data as modifications (as described below) 
rather than statistical adjustments. The datasets were 
adjusted to account for missing age and sex variables, 
differences in case definitions (complicated and uncom-
plicated chlamydial infections), referrals between non-
specialist and specialist services, and missing data for 
certain years. Some adjustments to the data could be 
undertaken using more than one possible method. To 
justify the methods used, sensitivity analyses, statisti-
cal tests and comparisons to other research were used 
(Table 1).
Unknown age group or sex
Due to missing fields or aggregated reporting, tests 
and diagnoses could be reported without known sex or 
age group, therefore in these instances tests and diag-
noses were reallocated according to the age and sex 
distributions seen in each year (see adjustment num-
ber 1 in Figure 2 and Table 1).
Between 2000 and 2008, diagnoses coming from spe-
cialist services were coded as either ‘uncomplicated’ 
or ‘complicated’ chlamydia (i.e. complicated when 
diagnosed with chlamydial PID and epididymitis). 
Complicated chlamydia diagnoses were not reported 
by age group. Based on a two-sample Kolmogorov-
Smirnov test, the age distributions for ‘complicated’ 
and ‘uncomplicated’ chlamydia diagnoses in special-
ist services between 2009 and 2011 were not signifi-
cantly different (borderline, p = 0.053). We therefore 
assumed the distributions were not significantly dif-
ferent between 2000 and 2008 and the ‘complicated’ 
diagnoses were reallocated into age groups according 
to the age distribution of ‘uncomplicated’ diagnoses.
Between 2003 and 2008, chlamydia tests in specialist 
services were reported by sex but not by age group. We 
therefore reallocated tests reported during this period 
into age groups according to the age group distribution 
of tests in 2009. This is based on analysis of variance 
tests (ANOVA) showing a non-significant difference 
between the age distribution of diagnoses between 
2003 and 2012 (p = 1.0) and a non-significant differ-
ence between the age distribution of tests between 
2009 and 2012 (the years where tests by age were 
reported, p = 0.9).
Non-reported data: age group
During the analysis period, there are two major gaps in 
reporting where no data were collected through national 
monitoring and surveillance systems: (i) Before 2003, 
the number of chlamydia tests in specialist services 
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Figure 3
Reported rates of chlamydia tests and diagnoses captured in specialist sexual health services and non-specialist services by 
sex and age group, Panels A), C) and E) show tests; Panels B), D) and F) show diagnosis rates, England, 2000–2012
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were not collected; and (ii) in non-specialist services, 
data on chlamydia tests and diagnoses were incom-
plete before 2012, this included non-reported data 
for 15–24-year-olds before 2008 and for > 24-year-olds 
before 2012. To produce plausible estimates of total 
activity during these periods we imputed these data 
(see adjustment number 2).
Firstly, in order to impute the number of chlamydia 
tests in specialist services between 2000 and 2002, 
we used logistic regression to estimate the linear trend 
in positivity (percentage of chlamydia tests resulting in 
a positive diagnosis) between 2003 and 2008. Using 
the trend in positivity observed between 2003 and 
2008, we predicted the positivity for 2000 to 2002. The 
model-predicted positivity trends were applied to the 
estimated diagnoses in order to estimate the numbers 
of tests in each year and age group from 2000 to 2002.
Secondly, we constructed minimum and maximum 
estimates of chlamydia testing coverage and diagnosis 
rates carried out in non-specialist services for 2000 
to 2011 to allow for the uncertainty arising from non-
reported data. Minimum estimates of chlamydia test-
ing coverage and diagnosis rates were based on data 
available in the datasets (NCSP statistical returns and 
aggregated laboratory returns), combined with test 
and diagnosis rates derived from GP settings (CPRD) 
in those years where data were incomplete. To esti-
mate maximum activity in non-specialist services, we 
used Poisson regression to estimate trends in test and 
diagnosis rates in the period where data from non-
specialist services were incomplete or not reported. 
We then applied these model-estimated incidence rate 
ratios to the most recent ‘complete’ year of non-spe-
cialist services data (2008 for 15–24-year-olds; 2012 
for > 24-year-olds).
Referrals from non-specialist to specialist 
services
Individuals cannot be followed between non-specialist 
and specialist services in the datasets as different 
identifiers are used. Since 2012, a diagnostic code to 
indicate referrals from non-specialist services with a 
Table 1
Rationale for methods used for adjustments to the data for estimating numbers of chlamydia tests and diagnoses by age 
group and sex, before and during the implementation of the National Screening Programme, England, 2000–2012.
Adjustment and adjustment numbera Assumption Data and evidence base for assumption
Reallocation of complicated 
chlamydia diagnoses into age groups. 
Adjustment number: 1
Assumes that the age 
distribution of diagnoses 
for complicated chlamydia 
in 2000 to 2008 was 
equivalent to that seen for 
uncomplicated chlamydia 
during the same period.
1) A Kolmogorov-Smirnov test was used to statistically compare the 
uncomplicated and complicated chlamydia diagnosis distributions. This 
test showed no significant difference between distributions. 
2) Alternatively, we could have reallocated complicated diagnoses 
captured between 2000 and 2008 according to the distribution of 
complicated diagnoses found in 2009. However, the results of a 
sensitivity analysis showed limited difference between methods 
(maximum percentage difference of 0.3% (range of 0.04–0.3%)).
Reallocation of tests between 2003 
and 2008 according to the age group 
distribution in 2009. 
Adjustment number: 1
Assumes that the age 
distribution of tests 
between 2003 and 2008 
was equivalent to that 
seen in 2009.
The rationale for this is based on two other observations: 
1) The age distribution for chlamydia diagnoses coming from specialist 
services between 2003 and 2008 were comparable to the age 
distribution of diagnoses in 2009 (ANOVA test non-significant). 
2) There was no variation in the age distribution for chlamydia tests 
coming from specialist services between 2009 and 2012 (ANOVA test 
non-significant).
Imputing data for 15 to 24-year-olds 
before 2008 and for > 24–year-
olds before 2012 in non-specialist 
services. 
Adjustment number: 2
Assumes that all testing 
in non-specialist services 
for 15–24-year-olds before 
2008, and in > 24-year-olds 
before 2012 followed a 
similar trend to that found 
in GP services.
We considered it a reasonable assumption that any changes seen in GP 
settings would also be reflected in other non-specialist services. 
Alternatively, we could have based this on the trend seen in specialist 
services. However, results from an audit of waiting times in specialist 
services show large increases in access to specialist services over this 
period following the first National Sexual Health Strategy [18]. Increases 
in testing outside of specialist services are therefore unlikely to have 
been of the same magnitude.
Imputing the number of chlamydia 
tests in specialist services between 
2000 and 2002. 
Adjustment number: 2
Assumes a consistent 
trend in positivity over 
time from 2000 to 2008.
This adjustment was based patterns seen within later years of the 
data. The trend in positivity on which this adjustment was made was 
calculated using 2003–2008 data, rather than 2003–2012, being 
the period before full implementation of the NCSP and the GUMCAD 
surveillance system, which may have led to some changes in the 
available data.
Allowing for referrals from non-
specialist to specialist services. 
Adjustment number: 3
Assumes a constant rate 
of referrals between non-
specialist to specialist 
services between 2000 
and 2012.
Our assumption is consistent with a previous study [21], which reported 
a steady referral rate between 2000 and 2004 from GP settings into 
specialist services.
ANOVA: analysis of variance; GP: general practice; GUMCAD:  Genitourinary Medicine Clinic Activity Dataset; NCSP: National Chlamydia 
Screening Programme.
aAdjustment number refers to the numbers found in the flowchart in Figure 2.
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chlamydia diagnosis into specialist services was intro-
duced (C4X code) [18,19]. We calculated the proportion 
of referrals in 2012, which ranged from 3.8% to 15.6% 
by age group. In both the minimum and maximum esti-
mates of activity in specialist services, testing cover-
age and diagnosis rates were adjusted to allow for 
potential duplication between services, based on the 
proportions of referrals in 2012, assuming the rate of 
referrals was constant across the period (see adjust-
ment number 3). While it is feasible that this has 
changed, this was considered a reasonable assump-
tion as Hughes et al. reported a steady referral rate of 
10% in 2000 to 2004 from GPs into specialist services 
[20], which is similar to the overall referral rate calcu-
lated for 2012 (8.4%).
Men who have sex with men
This dataset was compiled with an aim to mathemati-
cally model heterosexual transmission of chlamydia. 
MSM were therefore removed from the minimum-activ-
ity estimate for specialist services (see adjustment 
number 4). Sexual orientation is not available for tests 
and diagnoses outside of specialist services, so this 
could not be adjusted for.
Results
Figure 3 shows the chlamydia testing and diagnosis 
rates by services according to the years and age groups 
before adjustments were made to the data.
Table 2 shows the compiled data sources for all genital 
chlamydia testing and diagnosis activity by age group 
and sex.
Between 2000 and 2008, there was a large range 
between minimum and maximum estimate scenarios 
for both testing coverage and diagnosis rates. For 
example, in 15–19-year-old women in 2000, diagnosis 
rates ranged from 891 to 2,489 diagnoses per 100,000 
persons. In both scenarios and across all age groups 
(15–44-year-olds), estimated testing coverage and 
diagnosis rates were higher in women than men.
In women and men of all age groups (15–44-year-olds), 
there was an overall increase in chlamydia testing cov-
erage and diagnosis rates from 2000 to 2012 in all set-
tings. The greatest increases in both testing coverage 
and diagnosis rates were seen among 15 to 24-year-
olds, with the greatest increase in this age group 
found between 2008 and 2010. From 2010 there was 
a small decline in testing and diagnosis rates among 
15–24-year-olds. Whereas the minimum estimate sce-
nario showed a large increase in estimated diagnosis 
rates in women from 2000, a more gradual increase 
was seen for the maximum estimate scenario. In both 
minimum and maximum estimate scenarios, estimated 
diagnosis rates were relatively stable from 2008 to 
2012 in women and men.
Discussion
We used data captured by a range of monitoring and 
surveillance systems to construct a dataset represent-
ing all genital chlamydia testing and diagnosis activity 
taking place in England between 2000 and 2012. Gaps 
in the available data mean there is considerable uncer-
tainty around the total amount of testing and diagno-
ses in the years before 2008. We therefore constructed 
minimum and maximum estimates to acknowledge this 
but set bounds on the uncertainty within the data.
The changes seen in chlamydia testing and diagno-
sis rates are in line with the evolution of the NCSP 
and chlamydia testing in England. An overall increase 
in testing and diagnosis rates were observed among 
15–44-year-olds, which is likely due to increased 
awareness and better practice of chlamydia testing in 
England. The greatest increase in rates were observed 
in 15–24-year-olds, relating to an increase in opportun-
istic testing targeted in under-25-year-olds, as part of 
the NCSP from 2003. A sharp increase was seen from 
2008 due to the nationwide implementation of the 
NCSP in 2008, accompanied by national targets for 
testing coverage. The decline in testing rates from 2010 
may be explained, in part, by the changes in targets for 
testing during this period [21].
The constructed dataset resulting from our work has 
several applications. From these findings we have a 
better understanding of the potential effects of the 
NCSP on testing coverage and diagnoses. However, 
this does not provide the complete picture, as further 
insight is needed to understand how prevalence and/
or incidence have changed in the context of the pro-
gramme. Mathematical modelling offers a means to do 
this and our constructed data can be used to param-
eterise such models to better quantify the public 
health impact of the NCSP. Our data can also be used 
to parameterise and validate mathematical models 
designed to explore optimum approaches to chlamydia 
control (e.g. by varying rates of partner notification or 
changing the population tested). The findings of such 
modelling would be of benefit beyond England as the 
principles of chlamydia epidemiology and likely impact 
of different chlamydia control measures would likely 
hold across many different countries. Findings from 
such analyses could therefore inform chlamydia con-
trol activities in Europe and elsewhere.
In addition, these data can serve as a reference for 
interpreting trends in chlamydia-related complications. 
For example, trend in rates in PID, a complication asso-
ciated with STIs including chlamydia, can be compared 
with chlamydia rates and determine if any changes 
reflected in one may be reflected in the other [22]. This 
is important for evaluation of the NCSP as an aim of 
the programme is to reduce associated complications 
through opportunistic screening. Again, findings from 
such studies would have relevance beyond England, as 
a better understanding the impact of chlamydia control 
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Ch
la
m
yd
ia
 te
st
in
g 
co
ve
ra
ge
 in
 w
om
en
 (p
er
 1
00
 p
er
so
ns
) 
Ch
la
m
yd
ia
 te
st
in
g 
co
ve
ra
ge
 in
 m
en
 (p
er
 1
00
 p
er
so
ns
) 
M
in
im
um
 e
st
im
at
es
 
M
ax
im
um
 e
st
im
at
es
 
M
in
im
um
 e
st
im
at
es
 
M
ax
im
um
 e
st
im
at
es
 
15
–1
9-
ye
ar
-o
ld
s 
20
–2
4-
ye
ar
-o
ld
s 
25
–3
4-
ye
ar
-o
ld
s 
35
–4
4-
ye
ar
-o
ld
s 
15
–1
9-
ye
ar
-o
ld
s 
20
–2
4-
ye
ar
-o
ld
s 
25
–3
4-
ye
ar
-o
ld
s 
35
–4
4-
ye
ar
-o
ld
s 
15
–1
9-
ye
ar
-o
ld
s 
20
–2
4-
ye
ar
-o
ld
s 
25
–3
4-
ye
ar
-o
ld
s 
35
–4
4-
ye
ar
-o
ld
s 
15
–1
9-
ye
ar
-o
ld
s 
20
–2
4-
ye
ar
-o
ld
s 
25
–3
4-
ye
ar
-o
ld
s 
35
–4
4-
ye
ar
-o
ld
s 
Ye
ar
 
20
00
 
3.
1
5.
5
2.
7
1.
1
9.
7
11
.1
5.
4
2.
4
1.
1
2.
9
2.
0
0.
8
2.
0
3.
9
2.
5
1.
0
20
01
 
3.
8
6.
6
3.
6
1.
5
11
.1
12
.8
6.
2
2.
7
1.
3
3.
5
2.
2
0.
8
2.
4
4.
7
2.
8
1.
2
20
02
 
4.
8
8.
5
4.
3
1.
9
13
.0
14
.9
7.
0
3.
1
1.
6
4.
4
2.
6
1.
0
3.
1
5.
8
3.
3
1.
4
20
03
 
6.
3
11
.2
6.
0
2.
8
14
.9
17
.1
7.
9
3.
5
2.
0
5.
4
3.
0
1.
1
3.
8
7.
0
3.
6
1.
5
20
04
 
8.
5
14
.1
7.
3
3.
6
16
.8
19
.3
8.
9
3.
9
2.
4
6.
2
3.
5
1.
3
4.
7
8.
1
4.
3
1.
8
20
05
 
10
.3
15
.6
8.
0
4.
0
19
.0
21
.5
9.
9
4.
4
3.
1
7.
1
4.
0
1.
5
5.
6
9.
2
4.
8
2.
0
20
06
 
11
.1
16
.3
8.
2
4.
1
21
.2
23
.8
10
.9
4.
9
3.
5
7.
8
4.
3
1.
6
6.
8
10
.4
5.
4
2.
2
20
07
 
15
.1
18
.7
9.
0
4.
5
24
.2
27
.2
12
.4
5.
5
5.
5
9.
3
4.
9
1.
8
8.
4
12
.1
6.
2
2.
5
20
08
 
27
.3
30
.4
9.
9
4.
8
27
.3
30
.4
13
.8
6.
2
10
.2
13
.4
5.
3
2.
0
10
.4
13
.9
6.
8
2.
8
20
09
 
35
.7
38
.8
10
.4
5.
2
35
.7
38
.8
14
.8
6.
8
16
.1
18
.8
5.
3
2.
0
16
.3
19
.3
7.
1
2.
9
20
10
 
43
.0
43
.3
10
.4
5.
2
43
.0
43
.3
16
.0
7.
5
23
.9
23
.3
5.
4
2.
1
24
.0
23
.9
7.
5
3.
1
20
11
 
39
.3
41
.6
10
.6
5.
3
39
.3
41
.6
17
.5
8.
4
19
.0
19
.8
5.
4
2.
1
19
.2
20
.6
8.
1
3.
4
20
12
 
33
.9
39
.9
19
.2
9.
3
33
.9
39
.9
19
.2
9.
3
14
.2
18
.2
7.
7
3.
0
14
.5
19
.2
8.
8
3.
7
Ch
la
m
yd
ia
 d
ia
gn
os
is
 ra
te
s 
in
 w
om
en
 (p
er
 1
00
,0
00
 p
er
so
ns
) 
Ch
la
m
yd
ia
 d
ia
gn
os
is
 ra
te
s 
in
 m
en
 (p
er
 1
00
,0
00
 p
er
so
ns
) 
M
in
im
um
 e
st
im
at
es
 
M
ax
im
um
 e
st
im
at
es
 
M
in
im
um
 e
st
im
at
es
 
M
ax
im
um
 e
st
im
at
es
 
15
–1
9-
ye
ar
-o
ld
s 
20
–2
4-
ye
ar
-o
ld
s 
25
–3
4-
ye
ar
-o
ld
s 
35
–4
4-
ye
ar
-o
ld
s 
15
–1
9-
ye
ar
-o
ld
s 
20
–2
4-
ye
ar
-o
ld
s 
25
–3
4-
ye
ar
-o
ld
s 
35
–4
4-
ye
ar
-o
ld
s 
15
–1
9-
ye
ar
-o
ld
s 
20
–2
4-
ye
ar
-o
ld
s 
25
–3
4-
ye
ar
-o
ld
s 
35
–4
4-
ye
ar
-o
ld
s 
15
–1
9-
ye
ar
-o
ld
s 
20
–2
4-
ye
ar
-o
ld
s 
25
–3
4-
ye
ar
-o
ld
s 
35
–4
4-
ye
ar
-o
ld
s 
Ye
ar
 
20
00
 
89
1.
1
1,
04
3.
1
25
6.
7
56
.5
2,
48
8.
6
1,
90
9.
5
50
2.
6
11
3.
3
23
5.
7
62
1.
8
26
8.
1
78
.8
38
7.
1
81
5.
7
34
3.
4
11
3.
5
20
01
 
98
7.
5
1,
16
2.
3
30
5.
5
62
.9
2,
58
9.
5
2,
01
2.
8
53
0.
8
11
7.
2
25
5.
7
71
7.
7
29
1.
7
81
.8
43
1.
7
92
5.
5
37
2.
9
12
0.
8
20
02
 
1,
13
0.
7
1,
29
3.
3
31
1.
3
67
.0
2,
75
6.
4
2,
18
2.
7
54
8.
9
12
0.
2
31
8.
6
84
9.
1
33
0.
6
87
.8
51
9.
3
1,
08
8.
3
41
2.
1
12
9.
4
20
03
 
1,
24
4.
1
1,
40
2.
0
32
7.
8
68
.3
2,
87
1.
2
2,
28
8.
0
56
4.
6
12
0.
0
35
6.
3
96
9.
4
34
5.
8
94
.0
58
9.
8
1,
24
1.
3
44
0.
2
13
4.
6
20
04
 
1,
50
8.
3
1,
53
8.
9
34
4.
7
73
.4
2,
95
2.
0
2,
38
8.
4
57
2.
3
11
8.
4
42
4.
5
1,
10
8.
8
39
0.
5
94
.8
67
4.
9
1,
38
3.
8
49
0.
9
13
8.
5
20
05
 
1,
57
6.
5
1,
58
8.
3
34
4.
6
64
.6
2,
96
8.
4
2,
40
8.
1
57
4.
8
11
8.
9
48
9.
4
1,
18
9.
2
40
8.
4
97
.2
73
6.
8
1,
46
0.
3
52
1.
0
14
3.
7
20
06
 
1,
59
4.
2
1,
56
8.
0
34
0.
3
68
.7
2,
95
4.
7
2,
41
7.
4
58
1.
6
11
5.
0
53
5.
0
1,
26
7.
3
43
9.
2
10
3.
8
81
1.
2
1,
57
2.
9
56
5.
8
15
5.
2
20
07
 
2,
02
2.
5
1,
78
2.
3
38
1.
3
74
.7
3,
03
4.
0
2,
51
0.
8
59
7.
1
11
9.
4
70
4.
0
1,
41
5.
6
47
4.
6
11
0.
7
91
2.
5
1,
69
6.
3
61
1.
7
16
4.
2
20
08
 
2,
97
9.
6
2,
51
6.
9
37
9.
3
68
.4
2,
97
9.
6
2,
51
6.
9
60
4.
0
11
7.
3
94
6.
9
1,
71
6.
1
47
7.
6
10
5.
4
95
7.
6
1,
75
1.
5
63
2.
6
16
3.
7
20
09
 
3,
03
3.
9
2,
62
1.
4
35
5.
2
59
.8
3,
03
3.
9
2,
62
1.
4
58
7.
2
11
6.
4
1,
02
0.
2
1,
85
4.
3
43
5.
3
99
.8
1,
03
2.
6
1,
89
5.
4
60
5.
8
16
3.
5
20
10
 
2,
97
2.
8
2,
59
8.
7
31
8.
9
61
.5
2,
97
2.
8
2,
59
8.
7
56
6.
2
11
5.
8
1,
04
9.
4
1,
87
9.
1
41
6.
3
94
.5
1,
06
3.
8
1,
92
8.
0
60
6.
0
16
3.
2
20
11
 
2,
78
6.
6
2,
54
7.
1
32
7.
2
64
.9
2,
78
6.
6
2,
54
7.
1
59
9.
3
12
0.
0
97
0.
9
1,
75
4.
0
41
4.
8
91
.4
98
9.
9
1,
82
9.
5
64
7.
0
18
4.
1
20
12
 
2,
79
1.
8
2,
63
9.
5
58
7.
6
11
7.
3
2,
79
1.
8
2,
63
9.
5
58
7.
6
11
7.
3
93
5.
5
1,
83
0.
2
58
9.
7
13
0.
0
95
3.
8
1,
91
3.
7
67
8.
7
18
6.
8
Ta
bl
e 
2
M
in
im
um
 a
nd
 m
ax
im
um
 e
st
im
at
es
 fo
r c
hl
am
yd
ia
 te
st
in
g 
co
ve
ra
ge
 a
nd
 d
ia
gn
os
is 
ra
te
s i
n 
15
 to
 4
4-
ye
ar
-o
ld
 w
om
en
 a
nd
 m
en
 a
cr
os
s a
ll 
se
rv
ic
e 
ty
pe
s.
9www.eurosurveillance.org
on complications is needed to inform decisions about 
how best to approach chlamydia control [11].
The main strength of our analysis is the use of data 
from well-documented and established datasets, in 
which the changes in coding, testing practices and gaps 
in the data are understood. There are, however, some 
limitations. While every effort has been made to use 
data-driven and evidence-based assumptions to adjust 
for missing data, it is possible that our estimates have 
resulted in some over- or under- estimation of activ-
ity. We used data on referral patterns in 2012 to de-
duplicate testing episodes between settings. However 
de-duplication of testing or diagnosis episodes is likely 
to be incomplete. For example, if an individual visited 
two different specialist services for the same testing 
episode, it would not be possible to remove the dupli-
cate record. For this analysis, only tests undertaken by 
publicly-funded services have been counted, as private 
tests are excluded as part of the data collection speci-
fication [13]. When dealing with data where the age and 
sex were unknown, we used statistical tests to guide 
our decision about the most appropriate distribution to 
apply to the data. In the case of complicated chlamydia 
diagnoses, our finding was of borderline significance 
meaning that we may have incorrectly allocated by age 
group. However, as complicated diagnoses made up 
a minority of diagnoses from specialist sexual health 
services over this period (< 3.5%) this is unlikely to have 
made a substantial difference to the resulting dataset. 
Sensitivity analysis showed that applying an alterna-
tive assumption (i.e. reallocate according to the age 
distribution seen in 2009) made negligible difference. 
It is feasible that reallocating tests of unknown age 
in 2003 to 2008 according to the age-group distribu-
tion of tests in 2009 may have introduced error, as the 
NCSP was being rolled out in these earlier years.
During the analysis period, more sensitive and specific 
chlamydia tests have become available [23]. There is 
potential for both false negative and false positive 
results to have occurred over this period due to imper-
fect sensitivity and specificity of enzyme immunoas-
say (EIA) tests in particular, which were phased out in 
England during the mid-2000s [23]. We did not adjust 
our estimated diagnosis rates for test performance, as 
the test platforms used were not routinely collected 
and the exact performance characteristics are difficult 
to apply given the absence of an agreed gold standard 
[24].
Given the nature of this work and the absence of data, 
there are limited sources in the literature to validate our 
estimates. However, findings from the second National 
Survey of Sexual Attitudes and Lifestyles (Natsal-2, a 
stratified probability survey of British general popula-
tion carried out in 1999–2000) are consistent with the 
estimated diagnosis rates calculated in this work. For 
example among 20–24-year-old Natsal-2 participants 
who had ever had sex, 0.7% (95% confidence inter-
val 0.2–2.0%) of men and 1.7% (1.0–2.9%) of women 
reported having been diagnosed with chlamydia in the 
last year [25]. In our constructed dataset, assuming that 
each diagnosis represents an individual, the minimum 
and maximum estimates of percentage tested in 2000 
was 0.6% to 0.8% in 20–24-year-old men and 1.0% to 
1.9% in women, thus falling within the 95% confidence 
limits of the survey-based estimates. Currently, we do 
not have other external validation methods.
While there is uncertainty in the absolute numbers of 
chlamydia tests and diagnoses estimated in the ear-
lier years of our analysis period, it is highly likely that 
testing and diagnosis rates did increase from at least 
the early 2000s onwards. This is especially the case 
among under-25-year-olds as the target age group for 
the NCSP, which was implemented on a phased basis 
in 2003 and achieved national implementation by 2008 
[9,26]. Data from the second and third Natsal studies 
in 1999–2000 (Natsal-2) and 2009–2011 (Natsal-3)) 
indicate that diagnoses have increased substantially 
over the decade, with the percentage of 16–24-year-
olds who reported a chlamydia diagnosis in the last 5 
years increasing from 1.5% (1.2–1.8) to 4.1% (3.6–4.7) 
in women and from 0.8% (0.5–1.1) to 4.0% (3.4–4.8) 
in men [4]. It is likely therefore that our maximum sce-
nario estimates of diagnoses in earlier years in women 
are an overestimate. However, we retained this liberal 
estimate of diagnoses in the maximum scenario as we 
could not narrow these plausible ranges further on the 
basis of the available data.
The problem of missing data from chlamydia surveil-
lance systems is not one limited to England. Surveillance 
systems across Europe are known to vary in their com-
pleteness with respect to diagnoses, and few countries 
routinely collect and report data on testing, which is 
invaluable in interpreting trends in diagnoses of chla-
mydia, given that it is a largely asymptomatic infection. 
So, could our approach be applied to other settings? 
Our analysis has highlighted the multiple complexities 
in undertaking such an exercise, even in the context 
of England, where surveillance systems are more com-
plete than many others in Europe and have included 
testing denominators for several years [8]. However, it 
is possible that multiple data sources from other coun-
tries may be combined in a similar fashion to ascertain 
minimum and maximum estimates, through applica-
tion of reasonable assumptions about the complete-
ness of the data or relationships between them. Such 
an undertaking would need to be carried out on a case 
by case basis, involving in-country experts with in-
depth knowledge of data collection systems as well as 
an understanding of healthcare systems and changes 
in policy and practice over time.
Conclusions
Our analysis provides plausible comprehensive esti-
mates of chlamydia testing and diagnosis activity 
in England from 2000. Since 2012, developments in 
monitoring and surveillance systems for chlamydia 
and other STI in England, embodied by CTAD and 
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GUMCADv2, have allowed a comprehensive record of 
chlamydia testing and diagnosis activity from a single 
data source with far less uncertainty, enabling more 
robust assessment and evaluation of the English NCSP 
in future years. It is possible that similar methods to 
ours could be used for data captured in surveillance 
systems in applicable countries across Europe, how-
ever, our analysis highlights the potential complexities 
faced when estimating testing and diagnosis activity 
from multiple and changing data sources. When exam-
ining trends over time using monitoring and surveil-
lance data or compiling data from different sources, we 
recommend that known limitations be carefully consid-
ered and addressed where possible.
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